Commissioner Olivér Várhelyi addressed the Annual Forum of the European Social Insurance Platform on October 15, 2025, outlining a multi-faceted approach to enhance innovation, affordability, and sustainability in EU health systems.
Innovating While Balancing Access and Costs Várhelyi emphasized the challenge of financial sustainability in healthcare, underscoring the need for investment in innovation that yields measurable savings. He highlighted the Health Technology Assessment regulation and the forthcoming European Health Data Space as critical tools for evidence-based decision-making by Member States. The proposed pharmaceutical reform package aims to stimulate new medicine development and foster generic competition through an effective Bolar clause, intended to reduce drug prices and improve access. This package is expected to simplify processes and accelerate market entry for affordable medicines, potentially benefiting EU patients and pharmaceutical companies debating market competition dynamics.
Reshaping Medical Devices and Ensuring Supply Security Addressing the medical devices sector, Várhelyi proposed a regulatory overhaul to cut red tape and harmonize procedures with patient safety at the forefront. Special pathways for small patient populations, including paediatrics and orphan devices, aim to prevent exclusion. Short-term measures seek to support SMEs and manufacturers for faster market access. While these reforms could increase regulatory compliance efforts for manufacturers, they promise enhanced innovation flows and patient access. The Critical Medicines Act is among the proposed initiatives to reduce EU dependency on external suppliers and secure supply chains, balancing supply security against potential procurement cost increases for health payers.
Policy Orientations and Stakeholder Impact Várhelyi’s proposals signal a tilt toward strengthening EU-level regulation and harmonization while aiming to maintain competitive markets and ensure patient access. Health industry stakeholders face an environment with more streamlined yet potentially stricter oversight. EU payers might bear upfront costs from procurement criteria beyond price but gain from improved supply resilience. National health authorities gain enhanced data and assessment tools to support efficient resource allocation.
Preventive and Long-term Health Strategies The Commissioner also stressed tackling population ageing and chronic disease prevention, revealing plans for an EU Cardiovascular Health Plan to promote lifelong health and contain future public spending growth. Additionally, an EU Biotech Act is planned to foster innovation throughout the biotech lifecycle, aiming to bridge the gap between laboratory discoveries and market applications.
In summary, Várhelyi’s speech outlined a concrete agenda with policy proposals featuring deadlines and regulatory reforms focused on promoting innovation, affordability, and sustainability amid geopolitical and demographic challenges. These proposals carry mixed implications for industry competitiveness, patient access, public payers, and regulatory authorities within the EU health ecosystem.
← Atlas › News › Health & Lifestyle